Literature DB >> 16334756

Benign retroperitoneal schwannoma: surgical consideration.

Yang Won Nah1, Jae-Hee Suh, Dae Hwa Choi, Byung Kyun Ko, Chang Woo Nam, Gyu Yeol Kim, Young Cheol Im, Hong Rae Cho.   

Abstract

Schwannoma, which arises from the neural sheath of peripheral nerves, is the most common benign tumor in the retroperitoneum in adults. Complete excision is the treatment of choice for retroperitoneal schwannoma. During surgery, it seems to be unnecessary to identify the small peripheral nerve from which it develops. Keeping a dry field, however, through meticulous control of fine vasculature is of primary importance to avoid inadvertent injury to any of the adjacent organs, large vessels or important nerves. There are few vessels, if any, on the anterior and lateral surfaces of the tumor. Numerous small vessels to and from the tumors are located at its posterior and medial (aortic) aspects, without forming large trunks. Harmonic scalpel may be a good armamentarium in this area. In conclusion, considering such multiple small tumor vessels running adjacent to the aorta, the surgeon should pay close attention to the course of central dissection of these tumors in the retroperitoneum.

Entities:  

Mesh:

Year:  2005        PMID: 16334756

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  3 in total

Review 1.  Juxta-adrenal Ancient Schwannoma: A Rare Retroperitoneal Tumor.

Authors:  Daniel A Wollin; Ganesh Sivarajan; Pratibha Shukla; Jonathan Melamed; William C Huang; Herbert Lepor
Journal:  Rev Urol       Date:  2015

2.  MR imaging features of benign retroperitoneal paragangliomas and schwannomas.

Authors:  Yanguang Shen; Yan Zhong; Haiyi Wang; Lu Ma; Yingwei Wang; Kun Zhang; Zhonghua Sun; Huiyi Ye
Journal:  BMC Neurol       Date:  2018-01-04       Impact factor: 2.474

3.  Laparoscopic resection of retroperitoneal benign neurilemmoma.

Authors:  Jung Hwan Ji; Joon Seong Park; Chang Moo Kang; Dong Sup Yoon; Woo Jung Lee
Journal:  Ann Surg Treat Res       Date:  2017-02-24       Impact factor: 1.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.